Alnylam halts hemophilia drug trial due to patient death, renewing worries over safety
September 07, 2017 at 10:29 AM EDT
The announcement by the Cambridge biotech on Thursday cut its market cap by around $1 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|